

Genetic Analysis (GEAN)

Expands the Product Portfolio



Genetic Analysis AS ("Genetic Analysis" or "the Company") has developed the GA-map®, a platform for diagnostic analysis of microbiomes — the collection of microorganisms in the body that support digestion, immunity, and overall health. The human microbiome market is growing fast, as its importance for health has been increasingly recognized, yet the field has so far lacked standardization. The GA-map® platform aims to standardize microbiome diagnostics, which is expected to generate high long-term sales growth with a CAGR of 35% from 2024-2028. With an applied EV/S multiple of 1.9x on 2027's estimated sales of NOK 40.6m and a discount rate of 12%, a potential present value per share of NOK 1.05 (1.11) is derived in a Base scenario.

Stable Financial Development

Genetic Analysis reported net sales of NOK 2.1m (2.0) in Q3-25, corresponding to a growth of 3% Y-Y and 6% in constant currency. Genetic Analysis continues the commercial rollout of the GA-map® platform by expanding the number of partner laboratories, which is expected to drive recurring reagent kit sales going forward and thereby support further growth.

Import Tariffs Affected the Gross Margin

The gross margin amounted to 64% (75.6%) during Q3-25, which was negatively affected by import tariffs in the U.S, adjusted for this the gross margin amounted to 75%, in line with last year. This points towards Genetic Analysis absorbing the cost to keep pricing unchanged to customers. If unchanged, we expect continued margin pressure of ~15 percentage points on U.S. sales and ~10 percentage points overall, assuming a similar geographical sales mix and have updated our forecasts accordingly.

Expanding the GA-map® Portfolio

Genetic Analysis continues to expand the GA-map® portfolio with new product launches of tests that support broader platform adoption and recurring reagent kit sales. The newly released GA-map® MHI GutHealth RUO test opens access to additional Luminex users, adding a new disease area and creating long-term recurring revenue potential through high-margin consumables. The Company also reached a key milestone in its IBD Precision Dx project, advancing toward a RUO launch and commercialization in 2026, which is expected to further drive growth in reagent kit sales.

Small Changes in Valuation Range

Following the Q3-report we have updated our forecasts, with a slight downward revision sales and gross margin forecasts, with the latter affected by import tariffs in the U.S. On the other hand, Genetic Analysis continues to show impressive cost control, leaving our margin estimates largely unchanged. Nevertheless, the somewhat slower forecasted growth results in a small revision in our valuation range to NOK 0.34 – 1.56 (0.38 – 1.71), with the Base scenario at NOK 1.05 (1.11).

VALUATION RANGE

Bear

NOK 0.34

Base

NOK 1.05


Bull

NOK 1.56

KEY INFORMATION

Share Price (2025-12-04)	0.73
Shares Outstanding	69,087,041
Market Cap (NOKm)	50.4
Net cash(-)/debt(+) (NOKm)	-13.5
Enterprise Value (NOKm)	36.9
List	Spotlight Stock Market
Quarterly report 4 2025	2026-02-27

SHARE PRICE DEVELOPMENT



OWNERS (SOURCE: THE COMPANY 2025-09-30)

= INSIDER

Bio-Rad Inc	24.0 %
Avanza Bank AB	9.9 %
Muen Invest AS	6.2 %
Ochrino AS	4.9 %
Nordnet Bank AB	4.0 %

Estimates (NOKm)	2025E	2026E	2027E	2028E
Sales revenue	17.5	28.9	40.6	52.0
COGS	-5.0	-8.4	-10.9	-13.2
Gross profit	17.7	23.4	32.7	41.8
Gross margin (adj.)	72%	71%	73%	75%
Operating expenses	-26.7	-28.9	-31.9	-35.1
EBITDA	-3.6	-0.2	5.4	10.4
EBITDA margin (adj.)	-50%	-11%	6%	14%
P/S	2.9	1.7	1.2	1.0
EV/S	2.1	1.3	0.9	0.7
EV/EBITDA	neg.	neg.	6.8	3.6
EV/EBIT	neg.	neg.	42.0	5.5

Table of Contents

Investment Thesis	3
Comment Q3-report	4-5
Company Description	6-7
Market Analysis	8-9
Financial Forecast	10-13
Valuation	14-15
Bull & Bear	16
Management & Board	17-18
Appendix	19-21
Disclaimer	22

ABOUT THE COMPANY

Genetic Analysis is a Norwegian diagnostic company with more than 15 years of experience in research and product development within diagnostics of the human microbiome. The Company has developed the diagnostic platform GA-map® for the analysis of microbiomes. The platform provides cost-effective, standardized, and consistent results, forming the basis for diagnosing patients' microbiomes. Test results are published directly via the Company's cloud-based software, eliminating the need for additional resources to interpret the data. Genetic Analysis has been listed on the Norwegian Spotlight Stock Market since 2021.

CEO AND CHAIRMAN

CEO	Ronny Hermansen
-----	-----------------

Chairman	Morten Jurs
----------	-------------


ANALYST

Namn	Axel Ljunghammer
------	------------------

Phone	+46 706 554 551
-------	-----------------


E-mail	axel.ljunghammer@analystgroup.se
--------	----------------------------------

Value Drivers




Potential value drivers in the short-term includes increased sales from the launch of GA-map® MHI GutHealth and DTC-test in China, as well as reagent kits, with a continued improved margin as a result. From a long-term perspective, the high estimated market growth constitutes a strong value driver, with Genetic Analysis having established a first-mover advantage in microbiome-based diagnostics through the patented GA-map® platform.

Historical Profitability




Genetic Analysis has a long-standing history of research and development related to the Company's GA-map® platform, which is why the Company has historically reported negative earnings and cash flow. However, the Company's growing sales, combined with effective cost control, have contributed to a gradually improving margin. The rating is based on historical profitability and is not forward-looking.

Management & Board



CEO Ronny Hermansen has over 20 years of experience in the international diagnostics industry, including his former role as Group CFO at Axis-Shield plc. Furthermore, the board is considered to have relevant experience to support Genetic Analysis in the Company's expected growth journey.

Risk Profile



As of the end of Q3-25, the cash position amounted to NOK 17.7m. With expectations of continued strong cost control and sales ramp-up, with increased profitability as a result, we view the financial position as strong. However, the Company remains in an early stage of commercialization, which entails uncertainties regarding future revenue generation according to Analyst Group.

20.9%
ESTIMATED
ANNUAL MARKET
GROWTH

FERRING
PHARMACEUTICALS

Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group. Ferring is a leader in reproductive medicine and maternal health and is also pioneering innovation in microbiome and urooncology therapies. Founded in 1950, privately owned Ferring employs over 7,000 people worldwide, has its own operating subsidiaries in more than 50 countries, and markets its products in over 100 countries.

NOK 52M
ESTIMATED
SALES IN 2028

High Market Growth Creates Long Growth Runway

The human microbiome has been referred to as a "newly discovered organ" and in recent years research has emphasized the interplay between gut health and the immune system, highlighting its essential role in well-being. Moreover, several diseases have been linked to alterations in the composition and function of the microbiome. Given these insights, strong market growth is projected in the coming years. Global Market Insights estimates an annual market growth rate of 20.9% from 2025 to 2034, reaching a valuation of USD 8.9bn. The primary growth driver is expected to be advances in research, which have revealed the microbiome's potential in therapeutics. As therapeutics become more readily available, the need for reliable diagnostic tools is expected to grow in tandem, both for selecting which patients that should receive treatment and for tracking therapeutic response over time, including the potential requirement for repeated dosing. Genetic Analysis has an established first mover advantage within microbiome-based diagnostics through the patented platform GA-map®, which was used to develop the first CE IVD-marked (In Vitro Diagnostic) product for mapping microbiomes, why Analyst Group argues that the Company is well positioned to capitalize on the expanding market.

Collaboration with Ferring Pharmaceuticals Validates the Market Shift and the GA-map® Platform

A validation of the markets shift towards a more diagnostic approach is Genetic Analysis partnership with Ferring Pharmaceuticals, which constitutes of the development of a rapid microbiome-based PCR test, combining Genetic Analysis' GA-map® platform with Ferring's Microbiome Health Index biomarker. The GA-map® MHI GutHealth test is expected to reduce processing time from weeks to hours, lowering costs, and enhance standardization in microbiome diagnostics. The test has been launched as a Research Use Only (RuO) product in 2025 and Genetic Analysis holds exclusive commercialization rights without royalty or milestone obligations to Ferring. The test will initially target patients suffering from *Clostridioides difficile* infection (CDI), which is eligible for treatment with Ferring's Rebyota drug, the first fecal microbiota product approved by the FDA. Hence, in the long-term, the test is expected to be used clinically to follow-up on how individual patients react on the Rebyota drug. This underscores the market shift towards diagnostics as more drugs within the human microbiome are approved. The launch is expected to drive growth for Genetic Analysis by adding a new product to the portfolio within a new disease area. Moreover, the test could also be applied to monitor microbiome balance in broader clinical settings, such as helping monitor microbiome recovery after antibiotics, offering additional growth opportunities for Genetic Analysis.

A Platform Strategy Driving Recurring and Growing Revenues

Genetic Analysis business model is based on the Company's GA-map® platform, where today's primary revenue driver is sales of reagent kits required to perform tests that serve as the basis for diagnosing patients' microbiomes. As more laboratories adopt the user-friendly platform with immediate result publication through the Company's cloud-based software, sales of reagent kits are expected to increase, generating recurring revenue streams with high gross margins, estimated to amount to 80-85%, even though import tariffs in the U.S. are affecting the gross margin to be lower in the country in the short-term.

Forecast and Valuation: Summary

Analyst Group estimates growing revenues in the coming years through recurring sales of reagent kits, the launch of GA-map® MHI GutHealth test in Q3-25, steadily growing service sales, and sales of instruments in the U.S. and Asia. This is estimated to result in a revenue CAGR of 35% during the years 2024-2028, corresponding to revenues amounting to NOK 52m in 2028, while gradually improving profitability to 14% EBITDA margin in 2028. With an applied EV/S multiple of 1.9x on 2027's estimated sales of NOK 40.6m, and a discount rate of 12%, a potential present value per share of NOK 1.05 is derived in a Base scenario.

Early Phase of the Commercialization Entails Uncertainties

Genetic Analysis remains in an early phase of the Company's commercialization, which entails uncertainties regarding future revenue generation. Analyst Group expects a shift in market focus towards diagnostics of microbiomes, which is estimated to favor Genetic Analysis, however, it remains unclear at what pace such a shift will materialize, affecting the Company's growth outlook. Moreover, the attractive market opportunities from the fast-growing human microbiome market is expected to attract competition. However, Genetic Analysis holds a first-mover advantage, as the GA-map® Dysbiosis Test is well-documented with more than 50 peer-reviewed publications and over 70 clinical studies, which Analyst Group considers a strong competitive advantage and validation of the platform and demand.



Comment on Q3-report

Sales Growth of 3%

NOK 2.1M NET SALES

The sales revenue amounted to NOK 2.1m (2.0), corresponding to a growth of 3%. Sales were negatively affected by currency effects, as USD/NOK has decreased in the last year, in constant currency the sales revenue grew 6%. The U.S. continues to be the most important market for Genetic Analysis and accounted for 71% of the total sales during Q3-25, which grew by 4% while sales in Europe decreased by 8%. In terms of sales per category, product sales, mainly attributable to reagent kits to conduct test on Genetic Analysis platform, accounted for 89% of revenues and grew 2%, while service revenues accounted for the rest of the 11% and grew 12%.

The third quarter is a seasonally weaker quarter due to the vacation period during the summer months, why a decrease in sales compared to the last quarter's NOK 5.9m is expected. Moreover, Genetic Analysis sales are expected to fluctuate between quarters based on activities and inventory level at partners and following a strong Q2-25 with 34% sales growth, a somewhat slower growth rate in Q3-25 was expected. Moreover, the newly launched GA-map® MHI GutHealth Reagent kit is not expected to have contributed significantly to the sales in the quarter, as it is expected to take some time to scale up sales, which is why the outcome of sales revenue in Q3-25 was relatively in line with our expectations.

Continues to Leverage on the Platform Strategy and Market Leadership Through New Launches

Genetic Analysis has continued to develop the Company's platform, the GA-map®, during the quarter, with development and launches of new products, to continue to leverage on the market growth. The primary growth driver is expected to be advances in research, which have revealed the microbiome's potential in therapeutics. As therapeutics become more readily available, the need for reliable diagnostic tools is expected to grow in tandem, both for selecting which patients that should receive treatment and for tracking therapeutic response over time, including the potential requirement for repeated dosing. To capitalize on this trend, as one of the first movers within microbiome diagnostics, Genetic Analysis has launched a new test, and reached an important milestone for another, in recent months.

LAUNCH OF GA- MAP® MHI GUTHEALTH

On September 24th, Genetic Analysis announced the launch of the GA-map® MHI GutHealth Reagent kit as a Research Use Only (RUO), which makes the test available for Luminex xMAP® users globally. The test, which is a collaboration with Ferring Pharmaceuticals, combines Genetic Analysis' GA-map® platform with Ferring's Microbiome Health Index (MHI) biomarker. Initially, the test will be used for recurrent *Clostridioides difficile* infection (rCDI) patients to assess microbiome imbalances and monitor treatment effects during microbiome restoration.

The business model for Genetic Analysis regarding the test follows a similar structure as other products in the Company's portfolio, which is to implement the GA-map® platform at customer sites, primarily laboratories that conduct tests to diagnose human microbiota and uses Luminex instruments. To perform tests, reagent kits from Genetic Analysis are required, which is the primary revenue source for the Company and as consumables, they contribute to recurring revenue with a gross margin of around 80%, paving the way for a scalable business model. The test is expected to drive growth for Genetic Analysis by adding a new product to the portfolio within a new disease area. While a significant financial impact is not anticipated in the short-term, as test sales are expected to scale gradually, we see substantial long-term potential in the recently launched test.

Moreover, after the end of Q3-25, on November 17th, Genetic Analysis announced that a milestone for the Company's ongoing IBD Precision Dx project was reached, where the biomarker panel development was completed. Genetic Analysis has previously communicated an anticipated completion of a Research Use Only (RuO) version of GA-map® IBD Dx, a new innovative biomarker for Inflammatory Bowel Disease (IBD), by Q4-25 and with the announced milestone, a commercialization, expected during H1-26, is getting closer. GA-map® IBD Dx is a microbiome-based diagnostic tool to predict disease progression and treatment response in IBD, enabling earlier and more personalized treatment.

Like other areas in which Genetic Analysis is involved, the current diagnostic instruments within the IBD field are considered insufficient, leaving a gap in the market for the Company to fill. GA-map® IBD Precision Dx will add a new product to the portfolio, thereby contributing to growth of recurring and high-margin reagent kit sales, which is expected to drive growth and margin expansion for Genetic Analysis.

64% GROSS MARGIN

Gross Margin Affected by Import Tariffs


The gross margin during the quarter amounted to 64% (75.6%) and was affected by import in the U.S. Adjusted for the import tariffs, the gross margin amounted to 75%, in line with the same period last year. The U.S. has introduced a 15% import duty on goods from Norway, where Genetic Analysis manufactures its reagent kits. With the gross margin now affected for two consecutive quarters, it appears that the Company is absorbing the impact of the tariffs while maintaining stable pricing for its customers. If the current situation persists, we expect these duties to continue exerting pressure on the Company's margins, reducing profitability by approximately 15 percentage points on U.S. sales and around 10 percentage points overall, assuming the geographical sales mix remains consistent with recent quarters.

Continued Strong Cost Control

The operating expenses amounted to NOK 4.3m (4.9), corresponding to decrease of 14%. The decrease is, like in the previous quarter, attributable to general cost savings and the fact that the IBD project is in a less costly phase. As a result of the decreasing cost base, the EBITDA-result amounted to NOK -1.8m, in line with the same quarter last year, despite the decreasing cost base. We reiterate our view that through estimated growing sales of reagent kits and new product launches, a high gross margin and strong cost control, we expect Genetic Analysis to be able to continue to strengthen profitability, even though results likely will fluctuate between quarters.

Genetic Analysis are showing accelerating growth and improved results.

Genetic Analysis financial development for each individual quarter, based on the last twelve months (LTM) at the respective point in time.



Source: Genetic Analysis quarterly reports

Stable Financial Position

NOK 17.7M CASH POSITION AT THE END OF Q3-25

The cash balance amounted to NOK 17.7m at the end of Q3-25, compared to NOK 25m at the end of Q2-25, corresponding to a decrease of NOK 7.2m. Operating cashflow before changes in working capital amounted to NOK -1.8m, while changes in working capital accounted for the lion's share of the negative cash flow, amounting to NOK -5.4m, which was mainly attributable to a decrease in trade payables. Analyst Group sees fluctuations in working capital as natural and expects the effect to reverse in the coming quarters. With a cash position of NOK 17.7m at the end of Q3-25 and expectations of continued strong cost control and sales ramp-up, with increased profitability as a result, we view the financial position as strong.

In conclusion, Analyst Group views Genetic Analysis Q3-25 report as stable and largely in line with expectations, with 3% sales growth despite currency headwinds and quarterly fluctuations. The Company continues to strengthen its market position through new product launches and steady expansion of the GA-map® platform, including the recently introduced GA-map® MHI GutHealth test and the milestone achieved in the IBD Precision Dx project, both of which add long-term growth potential through high-margin, recurring reagent kit revenues. While import tariffs temporarily pressured gross margins, underlying profitability remains supported by strong cost control and a lean operating model. With continued product diversification, expanding diagnostic relevance, and a solid cash position of NOK 17.7m, Genetic Analysis is well positioned to drive margin expansion and sustained growth as sales ramp up in the coming quarters.

Genetic Analysis is a science-based diagnostic company founded in 2008 that is a pioneer in the human microbiome field and has over 15 years of expertise in research and product development. The Company has developed the GA-map® technology platform for standardized and targeted microbiota analysis, a market that lacks a standardized diagnostic test. The platform includes various products and services to satisfy a wide range of use cases, ranging from diagnosing patients to Research-use-Only (RuO). The Company also has ongoing strategic product development to address the expected needs in the market, including a diagnostic tool for IBD.

GA-map® Platform – Current product and service portfolio

GA-map® Dysbiosis Test – Detects and characterizes dysbiosis

The GA-map® Dysbiosis Test is a CE-IVD-approved diagnostic tool for gut microbiota analysis, which serves as a complementary diagnostic tool for IBS, IBD, leaky gut syndrome, and other gut-related disorders. Using the GA-map® Analyzer software, it ensures quality-controlled result calculation. The test identifies microbiome imbalances by comparing samples to a validated reference, presenting findings through a Dysbiosis Index (DI) score, and a functional bacteria analysis. Results are standardized, reproducible, and available within 2–3 days.

GA-map® Discovery – A microbiota research assay

GA-map® Discovery is a Research-Use-Only (RuO) assay which expands Genetic Analysis focus on clinical research. Based on proprietary technology, it provides researchers with a user-friendly tool to identify bacterial profiles and validate exploratory findings through its built-in databases.

GA-map® Sample Collection Kit

The GA-map® Sample Collection Kit enables reliable at-home fecal sampling for nucleic acid analysis, preserving sample integrity. CE-IVDR-approved, it is available for researchers, laboratories, and as an OEM product for commercial partners.

Service laboratory

Genetic Analysis service laboratory in Oslo offers complete microbiota profiling analysis for customers without the required instrumentation. Serving clients worldwide, the laboratory provides standardized, clinically validated microbiota assessments for all GA-map® assays.

GA-Map® Direct to Consumer

Genetic Analysis are offering consumer tests through the GA-map®, the first one has been developed in collaboration with Prokarimi AS, launched in August 2024. The test leverages the GA-map® platform's validated microbiome testing technology, i.e., a diagnostic approach where the results are compared to a predetermined reference range, developed through clinically validated studies and with fast results. Moreover, in a collaboration with Thalys Medical Technology Group, a DTC-test towards the Chinese market has been developed. The test has now been launched and Thalys distributes tests in China based on the GA-map® technology.

GA-map® MHI GutHealth Test

Genetic Analysis, in collaboration with Ferring Pharmaceuticals, has developed a companion diagnostic test under a commercial agreement signed in December 2024, called GA-map® MHI GutHealth marker. The first Research-Use-Only (RuO) product has been launched in Q3-25, which makes it available for Luminex xMAP® users globally. The test aims to support clinicians with a rapid, microbiome-based tool for treatment monitoring and patient stratification. The initial focus will be on patients who suffers from Clostridioides difficile infection (CDI), but in the long-term the test has the potential to support clinical decision-making in patient groups where antibiotic-associated microbiome imbalance plays a critical role.

Illustration of products



GA-map® Platform – Product Development Projects

GA-map® IBD Dx

Genetic Analysis is developing a diagnostic tool to predict disease progression and treatment response in IBD, enabling personalized treatment. Supported by the Research Council of Norway, the project involves the University of Gothenburg and Akershus University Hospital. Clinical recruitment is nearly complete, with the aim to have an RuO version of the diagnostic test available by Q4-25 and expected commercialization in H1-26.




REAGENT KITS
CONTRIBUTES TO
RECURRING
REVENUES

Business Model

Genetic Analysis' business model is based on implementing the GA-map® platform at customer sites, primarily laboratories that conduct tests to diagnose human microbiota. To perform these tests, an instrument from Luminex is required, which is already widely used in laboratories globally. However, Genetic Analysis acts as a distributor of these instruments in all markets outside of Europe, where Luminex handles sales directly. Additionally, reagent kits that Genetic Analysis provide are required to conduct tests; these are sets of chemicals that react with biological samples to establish a diagnosis. As consumables, they contribute to recurring revenue, and the test results are then automatically generated through the Company's cloud-based software, the GA-map® Analyzer.

Genetic Analysis' largest product today is the Dysbiosis Test reagent kit, a clinically validated and CE-IVD approved diagnostic test designed for use in molecular laboratories. Through the Company's software, the Dysbiosis Index (DI) score is calculated, where each sample result is converted into an easy-to-understand report. Each time a laboratory conducts tests, these reagent kits are required, generating recurring revenue for Genetic Analysis once the platform has been installed in a lab. Furthermore, the reagent kits are expected to have a high gross margin, expected to amount to 75-85%.

Finally, Genetic Analysis also has a business segment that offers services, primarily related to the Company's own laboratory, where tests are performed for customers without the appropriate instrumentation. In such cases, the Company charges a fee for the conducted tests.



Strategic Outlook

Potential Growth Drivers

1

Short-term: Install the GA-map® platform at more laboratories

2

Short- to midterm: Increased sales from the launched development projects

3

Long-term: Products within new disease areas through the GA-map® platform

The most important strategic initiative for Genetic Analysis to drive growth in the short term is to get the GA-map® platform installed at more laboratories, thereby generating recurring sales of reagent kits. The sales strategy includes distribution through selected partners and the Company's own sales department. A new distribution model was finalized in 2023, under which trusted partners sell GA-map® products directly to laboratories, ensuring global reach and facilitating logistics solutions. This means, among other things, that Genetic Analysis has discontinued instrument sales in the European market, where sales are now handled by the manufacturer Luminex, as instrument sales generate lower margins. It should also be noted that many laboratories already have the required Luminex instrument installed, which Genetic Analysis can target through distributors and the Company's own sales force, eliminating the need to sell the instrument.

Moreover, Genetic Analysis has ongoing development projects scheduled to launch, constituting an additional strategic initiative to drive growth. Two development projects, GA-map®-China, a microbiome test for the Chinese market, and GA-map® MHI GutHealth, a rapid microbiome-based PCR test has been launched during 2025. Additionally, the Company has an ongoing development project called GA-map® IBD Dx, addressing disease progression and treatment response in IBD, expected to be finalized as a Research-use-Only (RuO) test during Q4-25. These projects aim to utilize the Genetic Analysis platform to add new revenue streams for the Company.

In the long term, there is additional potential to drive growth by launching new products based on the GA-map® platform in new disease areas. Genetic Analysis may collaborate with partners in research and development to advance existing, or new, versions of the GA-map® for use in other disease areas, including for example type 2 diabetes and colorectal cancer.


20.9%
ESTIMATED
MARKET GROWTH

Increasing Interest in the Role of Microbiome in Health and Disease Drives Strong Market Growth

The human microbiome has been referred to as a “newly discovered organ,” and in recent years, research has emphasized the interplay between gut health and the immune system, highlighting its essential role in well-being. Moreover, several diseases have been linked to alterations in the composition and function of the microbiome. Given these insights, strong market growth is projected in the coming years. Global Market Insights estimates an annual market growth rate of 20.9% from 2025 to 2034, reaching a valuation of USD 8.9bn by the end of the forecast period.

The primary growth driver is anticipated to be advances in research, which have revealed the microbiome’s potential in therapeutics, particularly for the treatment of infectious diseases, metabolic disorders, and immune-related conditions. As a result, companies are focusing on developing therapeutics that modulate or restore healthy microbiota, driving market expansion. The current market value is primarily attributable to the value of probiotics, prebiotics, and services in research and clinical development, as approved products within both In Vitro Diagnostics and the pharmaceutical sector remain insufficiently developed or absent. However, awareness among researchers, pharmaceutical companies, clinicians, patients, and investors has increased. Global Market Insights highlights that the demand for microbiome-based diagnostics and therapeutics is increasing as healthcare systems adopt personalized approaches, tailoring treatments based on an individual’s microbiota. This trend is expected to drive demand for a well-functioning routine diagnostic tool, such as the one offered by Genetic Analysis to the market.

The global human microbiome market is expected to grow with a CAGR of 20.9%.



Source: Global Market Insights

Another market report, from Grand View Reseach, estimates that the global microbiome analysis market will grow by a CAGR of 10.5% until 2030 driven by the expanding understanding of the microbiome’s essential influence on human health, disease prevention, and the development of personalized medical approaches. In this report, Genetic Analysis was mentioned as a leading company within the field, which serves as a clear validation of the Company’s platform according to Analyst Group.

Genetic Analysis is a Pioneer Within Microbiome Diagnostics

With the growing market, an increasing number of microbiota tests are being conducted. At the same time, these tests are primarily conducted using research-based platforms and in-house developed assays, highlighting the need for a standardized and reliable test for the clinical diagnosis of the micro-biome. Genetic Analysis’ patented platform GA-map® was used to develop and commercialize the first clinically validated and CE-IVD approved test for microbiome analysis, the GA-map® Dysbiosis Test. As the test identifies microbiome imbalances by comparing samples to a validated reference and presents findings through a Dysbiosis Index (DI) score, the GA-map® platform aims to standardize microbiome diagnostics.


The Company also holds several patent families covering platform technology, algorithms, and profiles related to treatment outcomes. More players in the microbiome field are expected to seek clinically validated solutions with CE-IVD approval due to the attractive opportunities presented by market growth. However, Genetic Analysis holds a first-mover advantage, as the GA-map® Dysbiosis Test is well-documented with more than 50 peer-reviewed publications and over 70 clinical studies, which Analyst Group considers a strong competitive advantage and validation of the platform.

**FIRST-MOVER-
ADVANTAGE**



Genetic Analysis is a Global Company with Presence in Several Markets

Market Share Human Microbiome Market



North America is the largest market within the microbiome space, with a market share of approximately 40% in 2023¹. This is attributed to factors such as a more flexible regulatory environment in the United States, which accelerates approval processes for new therapies and diagnostic tools, and higher levels of investment in research and development compared to Europe. In November 2022, the FDA approved Rebyota, the first fecal microbiota product approved by the agency, and several additional products are in well-advanced clinical development phases, supporting further market growth in the U.S. In 2024, sales in the U.S. accounted for 67% of Genetic Analysis’ total revenue, where Analyst Group views the market as a key strategic focus for the Company due to its size and associated opportunities.

Nevertheless, there are uncertainties regarding the U.S. market related to tariffs, as the country has announced a 15% tariff on imported goods from Norway, where Genetic Analysis manufactures its reagent kits. However, several industry organizations within the medical device sector have expressed concern over the fact that medical devices are not exempt and have urged the administration to grant such exemptions to avoid increased costs and potential disruptions to healthcare services. During 2025, Genetic Analysis gross margin has been affected by import duties in the U.S. market. If the current situation remain, we expect the tariffs to continue to affect the Company’s margin going forward.

The Asian market, which represents an estimated market share of 25%, represented 15% of Genetic Analysis’ sales in 2023 and 2% in 2024. According to Skyquest, Asia is expected to be the fastest-growing region in the coming years. Genetic Analysis is expected to appoint additional partners to act as distributors in the region to expand market penetration and the Company has launched a consumer test on the Chinese market. Lastly, the European market remains an important region, constituting 31% of sales in 2024. The Company’s key European markets include Germany, Austria, Benelux, Poland, the U.K., and France.

Consumer Tests are the Fastest Growing Market Segment – But Concerns of Reliability

The consumer market is expected to be the fastest-growing segment within the microbiome field, driven by increasing awareness of health and the microbiome’s role in it. A growing number of consumer tests are being introduced to the market, reflecting increasing interest across digital channels, particularly tests that generate gut health reports, and, in certain cases, provide personalized dietary recommendations based on the results. However, the recent increase in consumer testing has raised concerns regarding reliability. In an article from The Guardian, experts concluded that there is currently no clinical use for DTC tests, as they are neither reliable nor regulated in the same way as laboratory-based diagnostics. Moreover, there is often high variability in results, and most tests take several weeks to deliver results, during which time the composition of the microbiome may change.

Genetic Analysis aims to address several of the current challenges in the consumer market with the Company’s DTC products. In partnership with Prokarimi, the Company ha launched a test which leverages the GA-map® platform’s microbiome diagnostic technology, comparing results to a predetermined reference range developed through clinically validated studies. The test is also expected to deliver faster results than competing solutions. As such, the DTC test is positioned to address several of the key disadvantages with other consumer microbiome tests. Moreover, Genetic Analysis has launched a microbiome test for the D2C market in China in collaboration with Thalys Medical Technology Group Corporation, which is specifically adapted to suit the Chinese market. The Chinese D2C microbiome testing market is expanding rapidly and, depending on the source, the market is expected to grow from USD 50–80m in 2023 to USD 200–300m in 2030, corresponding to a CAGR of 20–30 %².

GENETIC ANALYSIS DTC-PRODUCT HAS A DIAGNOSTIC APPROACH

Benefits with GA-map® DTC-test



Standardized results through a reference range



Reference range conducted through clinically validated studies, creating higher reliability



Faster results than competing products



¹Source: Precedence Research

²Sources: Grand View Research, iReserach



Financial History

Genetic Analysis has a long-standing history of research and development related to the Company's GA-map® platform, which is why the Company historically has reported negative earnings and cash flow. However, revenue has grown steadily, with a revenue CAGR of 29% during the years 2020–2024. This growth is attributable to broader installation of the GA-map® platform across laboratories, resulting in recurring revenue from reagent kit sales, which increased from NOK 2.9m in 2020 to NOK 13.2m in 2024, corresponding to a CAGR of 45%.

Revenue growth decelerated in 2024, amounting to 12%, primarily due to the Company's updated distribution model, in which instrument sales in Europe have been discontinued and are now handled directly by the manufacturer. As a result, revenue from instruments amounted to NOK 0.1m (1.5) in 2024, representing a decrease of 92%.





At the same time, product revenue—primarily consisting of recurring sales of reagent kits—continued to demonstrate strong growth, increasing by 37% in 2024 and accounting for 83% of total revenue. This strategic shift is partly explained by the low-margin nature of instrument sales. It should also be noted that the updated distribution model is limited to the European market, which is why instrument sales are still estimated in the U.S. and Asia.

The United States has historically been Genetic Analysis' largest and most important market, accounting for 69% of total revenue in Q3-25 LTM. The United States is expected to remain the key market for Genetic Analysis, given the size of the market and the anticipated increase in sales-related investments in the country moving forward.

Genetic Analysis' gross margin is expected to vary across product categories. Reagent kits are expected to generate a high gross margin, which amounted to 80% for the Company in 2024, when 83% of revenue was derived from reagent kits. The gross margin in services depends heavily on the number of tests analyzed in each set, where lower test volumes result in lower margins, while maximum volumes are expected to generate margins comparable to those of reagent kits. Lastly, instrument sales are expected to yield low double-digit margins. Therefore, the product mix, as well as the number of tests performed within the service revenue in a given quarter, is considered the primary reason why the gross margin fluctuated between 65–82% from 2020 to 2024.

In terms of costs, Genetic Analysis has worked to reduce the cost base over the past year in order to accelerate the path to profitability. The strategy has been to streamline the organization, while development projects have entered less capital-intensive phases, resulting in a 28% decrease in operating expenses (excluding D&A) in 2024, which has continued in 2025, where OPEX has decreased 17% Y-Y in Q3-25 (LTM). Furthermore, the Company has initiated a strategy focused on co-funding development projects with partners, enabling the Company to avoid bearing the full investment cost for new products.

Financial Overview



A GROWING
NUMBER OF
LABORATORIES
USING GA-MAP®
IS ESTIMATED

STRONG
PRODUCT-
MARKET FIT

Revenue Forecast 2025-2028

Interest in the microbiome has increased significantly in recent years, as research has established its essential role in health. A wide range of diseases has been linked to imbalances in gut microbiota composition, known as dysbiosis. We expect Genetic Analysis to continue expanding the number of laboratories with the GA-map® platform installed going forward. This is based on favorable market trends, with Genetic Analysis positioned as a pioneer within the microbiome diagnostics space and therefore expected to capitalize on the increased interest.

Going forward, Analyst Group anticipates a shift in market dynamics, with increased attention directed toward microbiome-based therapeutics and, importantly, diagnostics. The approval of the first FDA-approved microbiome-based therapeutic, Rebyota, in 2022 marked a turning point — signaling the transition from a research-dominated market to one increasingly focused on practical clinical applications, including diagnostics. Currently, most microbiome testing is conducted using research-based platforms and in-house developed assays. In this context, Genetic Analysis stands out with the GA-map® platform, the only CE-IVD-marked and patented routine diagnostic test in the field, offering a strong product-market fit. As the market matures and places greater emphasis on validated diagnostics to complement therapeutic advances, we expect more laboratories to adopt standardized diagnostic tools, which in turn is expected to drive increased installations of the GA-map® platform.

Nevertheless, a market shift is expected to be slow-moving and require time, which is why installations at new laboratories are not expected to accelerate exponentially but grow steadily. However, the overall market trend is expected to create a long-term growth runway for Genetic Analysis, which supports the expectation that new installations continue to grow over an extended period. With a larger installed base, the Company is expected to expand the recurring revenue from reagent kits, which historically is primarily related to the Company's largest product, GA-map® Dysbiosis Test. Recurring revenues from reagent kits for the product is projected to increase from NOK 13.2m in the year 2024 to NOK 41.1m in the year 2028, corresponding to a CAGR of 33%.

We expect Genetic Analysis' collaboration with Ferring Pharmaceuticals to serve as an additional growth driver. The partnership has resulted in the development of the GA-map® MHI GutHealth test, combining the Company's GA-map® platform with Ferring's biomarker. Launched in Q3-25 as a Research Use Only (RUO) test in the U.S., it initially targets patients with *Clostridioides difficile* infection treated with Rebyota and is expected over time to be applied clinically to monitor patient response to medication. The launch is expected to drive growth for Genetic Analysis by adding a new product to the portfolio within a new disease area. Analyst Group estimate that the launch will have limited effect on 2025's sales, amounting to NOK 0.3m, but thereafter grow to NOK 7.1m in 2028.

Primary Growth Drivers

1

Recurring revenues from
reagent kits from the
Dysbiosis Test

2

Launch of GA-map® MHI
GutHealth

3

Service sales from the own
laboratory


Moreover, Genetic Analysis service laboratory, where tests are performed for customers who do not have the appropriate instrumentation for a fee, is estimated to generate growing sales as the market for microbiota research continues to grow. However, service revenue is expected to fluctuate between quarters and years depending on the timing of smaller labs wanting to receive test results as well as clinical research projects in industry and academia. Services generated NOK 2.6m in sales in 2024, which is estimated to grow to NOK 2.9m in 2028.

Genetic Analysis has recently launched a microbiome test for the Chinese consumer market in collaboration with Thalys. The business model is to provide Thalys with reagent kits and proprietary software. As revenue will be generated based on the number of tests sold, with no further financial investments will be required in the collaboration, this enables a low-risk business model while having potential to generate significant revenue, given a successful launch. However, given the early stage and uncertainties in sales, Analyst Group has taken a conservative approach in our forecasts regarding the test, estimating an annual revenue of approximately NOK 2m from 2026, with potential for upward revision given a successful launch.

In summary, growing recurring revenues from GA-map® Dysbiosis Test reagent kits, an introduction of GA-map® MHI GutHealth test and a consumer test on the Chinese market during 2025, steadily growing service sales, and sales of instruments in the U.S. and Asia, is estimated to generate a revenue CAGR of 35% during the years 2024-2028, corresponding to revenues amounting to NOK 52m at the end of the forecast period. Moreover, we see potential that Genetic Analysis can add additional revenue streams by leveraging the GA-map® platform for new products. One such opportunity lies in the ongoing IBD Precision Dx project, where the Company are a new innovative biomarker for Inflammatory Bowel Disease (IBD), which could serve as an additional growth driver, with expected commercialization in H1-26.

Revenue is expected to grow at a high and steady pace during the forecast period.

Estimated Revenue and Revenue Growth



Source: Analyst Group estimates

Gross Margin 2025-2028

Genetic Analysis gross margin has shown volatility between quarters and years and is expected to fluctuate across product segments. The primary rationale behind the updated distribution model, i.e. exit instrument sales in Europe, is the low-margin profile of that business segment. Sales are instead managed by the manufacturer, Luminex. As a result of this model shift, instrument sales decreased by 92% in the year 2024, while the overall gross margin increased from 69% to 80%.


The gross margin for reagent kits is expected to fluctuate between 75–85% depending on the customer. However, Genetic Analysis gross margin has been affected by import duties in the U.S. during 2025, as the U.S. has introduced a 15% import duty on goods from Norway. If the current situation persists, we expect these duties to continue exerting pressure on the Company's margins, reducing profitability by approximately 15 percentage points on U.S. sales and around 10 percentage points overall, assuming the geographical sales mix remains consistent with recent quarters.

Regarding service revenue, gross margin is expected to be highly dependent on the number of samples analyzed per run. Fewer tests result in a lower margin, while maximum test volumes are expected to generate a margin similar to that of reagent kits. As service revenue is projected to increase, Analyst Group expects Genetic Analysis to optimize test utilization, resulting in an increase in gross margin from approximately 68% in the year 2025 to approximately 74% in the year 2028 within service segment.

Some instrument sales are still expected in the United States and Asia, which are estimated to have low double-digit gross margins and are thereby expected to weigh down the overall gross margin for the Company somewhat, even though volumes are expected to be low. In conclusion, Analyst Group estimates the gross margin to decrease slightly throughout the forecast period, from ~80% in 2024 to ~75% in 2028, where improved margins within services are offset by a declining margin in reagent kits due to tariffs and increased competition and the continued low-margin instrument sales.

Analyst Group estimate the gross margin to amount to fluctuate between 72-75% during the forecast period.

Estimated Revenue, Gross Profit and Gross Margin



Source: Analyst Group estimates

IMPORT DUTIES
IN THE U.S. ARE
AFFECTING THE
GROSS MARGIN

¹Adjusted for other income


Operating Expenses 2025-2028

Genetic Analysis external expenses are expected to primarily consist of office costs, administrative expenses, and marketing. The Company has successfully reduced the cost base in recent years, with a 29% decrease in the last year, driven by organizational streamlining and development projects transitioning into less capital-intensive phases. Looking ahead, Genetic Analysis' commercial investments are expected to expand moderately, with a primary focus on the United States market. The United States is the largest microbiome market, partly due to a more advanced research and development culture, which is expected to create the largest growth opportunities for Genetic Analysis within that market. These investments are expected to be commercial, primarily related to the expansion of the sales organization.

We estimate the personnel to grow from 16 at the end of 2025 to 22 at the end of 2028, with personnel costs to grow from NOK 14.7m in 2025 to NOK 23.1m in 2028. Regarding external expenses, we estimate these to grow from NOK 6.3m in 2025 to NOK 8.3m in 2028, primarily related to increased marketing efforts.

Genetic Analysis cost base is expected to grow slightly, attributable to commercial investments

Estimated External Expenses and Personnel Expenses, 2024-2028E




Source: Analyst Group estimates

Nevertheless, operating expenses are expected to grow at a slower pace than revenue, resulting in gradually increasing profitability over the forecast period, with an EBITDA margin, adjusted for other income, projected to reach 14% in 2028. The forecasts are based on the view that Genetic Analysis is expected to prioritize growth over profitability in the coming years to capitalize on strong market expansion and the attractive market position the Company has established as a first mover in the field of human microbiota diagnostics. This strategic focus on increasing the number of GA-map® platform installations across laboratories is considered well-justified, and higher profitability is anticipated to materialize at a later stage as the Company matures. Given the recurring nature of revenues and a high gross margin of approximately 75–85%, an operating margin exceeding 20% is considered achievable in the long term.

**EXPECTED
ACHIEVABLE
OPERATING
MARGIN OF 20%**

Analyst Group expects Genetic Analysis to prioritize growth over profitability in the coming years.

Estimated Revenue, EBITDA and EBITDA margin, adjusted for other income, 2024-2028E



Source: Analyst Group estimates

¹Adjusted for other income

Valuation: Relative Valuation

The valuation of Genetic Analysis is based on a relative valuation, where we have chosen to compare the Company with other Nordic diagnostics companies of similar size. However, given the Company's unique platform and position in the market as a pioneer within diagnostics of the microbiota, it is challenging to find direct comparable companies with a similar product or addressable market, making a broader selection of diagnostic companies necessary to illustrate how the market values the sector. Accordingly, the peer group consists of diagnostic companies operating in various fields, some of which are focused on gastrointestinal diagnostics, while others are active in different diagnostic areas. Nonetheless, Analyst Group considers these peer companies to be relevant, as they are of similar size, are in a comparable expansion phase with similar growth prospects and share commonalities in business models and target customers. The table below provides a comparison between Genetic Analysis and selected peer companies in terms of size, financial position, growth, and profitability.

KPI's	Market Cap	Enterprise Value	D/E Ratio	Revenue growth	Gross margin	EBIT margin	EBIT margin	EV/S	EV/S	EV/S
	NOKm	NOKm	x	CAGR 2024-2027E	LTM	LTM	2027E	2025E	2026E	2027E
Gentian Diagnostics	848	764	0.2	23%	55%	13%	23%	4.2	3.3	2.6
Biohit	640	595	0.4	13%	68%	18%	17%	3.3	2.8	2.4
Devyser	1,928	1,892	0.4	26%	82%	-5%	28%	6.9	5.2	4.1
Level Bio	25	24	6.7	n.a.	54%	-13%	n.a.	n.a.	n.a.	n.a.
Virogates	229	192	4.0	n.a.	47%	-248%	n.a.	n.a.	n.a.	n.a.
Boule Diagnostics	246	444	1.7	0%	43%	3%	12%	0.8	0.8	0.7
Average	653	652	2.2	16%	58%	-39%	20%	3.8	3.0	2.5
Median	443	519	1.0	18%	55%	-1%	20%	3.7	3.0	2.5
<i>Genetic Analysis</i>	<i>50</i>	<i>37</i>	<i>0.5</i>	<i>37%</i>	<i>77%</i>	<i>-88%</i>	<i>-5%</i>	<i>2.1</i>	<i>1.3</i>	<i>0.9</i>

Genetic Analysis vs Peers

Genetic Analysis has a **lower** Market Cap than comparable companies.

Genetic Analysis is expected to achieve **lower** profitability than comparable companies in 2027.

Genetic Analysis is expected to achieve **higher** revenue growth than comparable companies.

As Genetic Analysis is expected to continue capitalizing on existing growth opportunities in the coming years rather than prioritizing maximum profitability, and since several comparable companies are not yet profitable, the relative valuation is based on revenue by applying an EV/S multiple to the estimated revenue for the year 2027. Within the selected peer group, the median EV/S multiple for 2027 is 2.5x. However, differences between Genetic Analysis and the peer group should be considered.

In terms of size, Genetic Analysis is a smaller company relative to the average among peers, which should justify a valuation discount due to a higher expected risk premium for smaller companies. Regarding the financial position, Genetic Analysis is still in the early stages of commercialization, has yet to generate sustainable positive cash flow, and is expected to prioritize growth over profitability in the coming years, which creates uncertainties compared to certain peers that have already achieved positive margins. However, Genetic Analysis has strengthened the cash position through a directed rights issue and subsequent offering, which provided gross proceeds of NOK 16.9m. This has created a robust financial position with cash that are expected to be sufficient until a sustainable positive cash flow has been achieved.

As another consequence of the early phase and focus on growth, Genetic Analysis are expected to show lower profitability, with a negative EBIT margin, adjusted for other income, in 2027, compared to an average EBIT margin of 20% among peers. However, it should be noted that the two smaller, less mature, and currently unprofitable comparison companies, Level Bio and Virogates, lack financial forecasts, which may distort the average profitability for the comparison group in the year 2027.

On the other hand, the Company's expected strategic focus and investments in growth are estimated to result in a high sales CAGR compared to peers, amounting to 37% for the years 2024–2027, compared to 18% for the comparison group. The higher estimated growth justifies a valuation premium, which is considered an appropriate strategic direction given the Company's position as a first mover in diagnostics within the human microbiome field, a market that remains small but is expected to grow rapidly. Lastly, Genetic Analysis has a higher gross margin, amounting to 77% LTM, compared to the peer median of 55%, which we argue implies a higher long-term profitability potential and justifies a valuation premium.

Based on this reasoning, Analyst Group considers that Genetic Analysis should be valued at an EV/S multiple below the peer group due to the smaller size and lower expected profitability, while on the other hand, Genetic Analysis is expected to demonstrate higher growth. We apply an EV/S multiple of 1.9x, which results in an Enterprise Value of approximately NOK 78m, based on the estimated 2027 net revenue of NOK 40.6m.

NOK 1.05 IN A BASE SCENARIO

To calculate the present value, a WACC of 12% is applied, and after adding net cash, this implies a potential present price per share of NOK 1.05 in a Base scenario.

Valuation: Discounted Cash Flow


The established relative valuation is supplemented by a discounted cash flow analysis to further support the valuation. The explicit forecast period in the DCF model spans the years 2025 to 2028, followed by a normalization period (2029-2034) and a terminal period. Analyst Group estimates that the EBITDA margin, adjusted for other income, will reach 14% in 2028, after which it is expected to continue to increase to 22% in 2033. In the long-term, we estimate that increased competition given the attractive market opportunities within the human microbiome diagnostics market will influence Genetic Analysis profitability, with an estimated EBITDA margin of approximately 18% in the terminal period. Furthermore, a terminal growth rate of 2% is assumed. The discount rate (WACC) is set at 12%, and based on the future discounted free cash flows, a value of NOK 1.23 per share is derived in a Base scenario.

The discrepancy compared to the relative valuation is assumed to be partly attributable to the fact that the relative valuation to a greater extent reflects the current market sentiment, where risk appetite for smaller companies with negative cash flow is low. The DCF model, on the other hand, places greater emphasis on the growth potential of Genetic Analysis, highlighting an attractive long-term growth opportunity and a business model that paves the way for strong profitability. Given this reasoning, we take a conservative approach and base our valuation of Genetic Analysis primarily on the relative valuation, considering the inherent uncertainty in forecasting cash flows far into the future, which is the case in the DCF model. However, we view the DCF as a relevant complementary tool that illustrates the value embedded in the Company's long-term growth potential in an attractive market.

Genetic Analysis is estimated to have a long growth runway given the strong estimated market growth and attractive position in the market as a first mover within diagnostics of the microbiota.

Valuation, summary

Valuation: Summary



Source: Analyst Groups valuation



Bull Scenario

Estimated Sales 2027E

NOK 51.1m

Applied EV/S Multiple

2.4x

Potential Share Price

NOK 1.56

Bull scenario

In a Bull scenario, the shift toward increased focus on therapeutics and diagnostics in the human microbiome market occurs at a faster pace, which benefits Genetic Analysis as a first mover in the field of microbiome diagnostics. As a result of this shift, the GA-map® platform is expected to be installed at a greater number of laboratories, creating recurring demand for reagent kits. Furthermore, customers are estimated to use higher volumes of reagent kits on average, driven by the larger operational scale of the laboratories compared to a Base scenario. Combined with a successful launch of GA-map® MHI GutHealth in the year 2025 and growing service revenues, revenue is projected to grow at a CAGR of 44%, increasing from NOK 16m in the year 2024 to NOK 68m in the year 2028.

A higher gross margin is estimated in a Bull scenario, driven by increased willingness to pay among customers, supported by the user-friendliness of the GA-map® platform, and improved efficiency in the service laboratory, where a greater number of samples can be analyzed per run, thereby reducing the cost per test. With a higher estimated gross margin and a cost base that is expected to remain stable, albeit slightly higher, despite the accelerated revenue growth, this results in improved profitability, where the EBITDA margin, adjusted for other income, is estimated to increase gradually and reach 25% in the year 2028.

Given the stronger financial development in a Bull scenario, Genetic Analysis is expected to achieve positive EBITDA in 2026, in contrast to the Base scenario where a positive EBITDA result is estimated in 2027. This would strengthen the Company's financial position and reduce the uncertainty regarding its ability to scale up. Consequently, a higher valuation multiple is justified in a Bull scenario, where an EV/S multiple of 2.4x is applied to the estimated 2027 sales of NOK 51.1m. This results in an Enterprise Value of approximately NOK 123m and with a discount rate of 12%, and after adding net cash, this implies a potential present price per share of NOK 1.56 in a Bull scenario.

Bear scenario

In a Bear scenario, the market is more sluggish regarding adoption of a diagnostic perspective and a standardized diagnostic system within the human microbiome field, why less installations of the GA-map® platform is conducted. Hence, we estimate less sales of the reagent kits to laboratories, as well as a lower price per kit, which results in a lower sales growth during the forecast period. The service revenue is estimated to remain stable at current levels, which amounted to NOK 2.6m in 2024. GA-map® MHI GutHealth is expected to contribute to increased sales by adding a new product to the portfolio within a new disease area for the Company, however, at lower levels compared to a Base scenario. Revenue is projected to grow at a CAGR of 8%, increasing from NOK 16m in the year 2024 to NOK 21.6m in the year 2028.

The cost base is expected to remain stable even in a Bear scenario; however, limited revenue growth would still result in Genetic Analysis facing challenges in covering the operating costs through generated sales. This would lead to sustained reported losses and negative cash flows. In such a scenario, additional external capital raises can not be ruled out in the long term to finance the Company's operations.

Given the weaker financial development in a Bear scenario, and the financial risk that follows, a lower multiple is justified, where an EV/S multiple of 0.8x is applied to the estimated 2027 sales of NOK 19.8m. This results in an Enterprise Value of approximately NOK 16m and with a discount rate of 12%, and after adding net cash, this implies a potential present price per share of NOK 0.34 in a Bear scenario.



Bear Scenario

Estimated Sales 2027E

NOK 19.8m

Applied EV/S Multiple

0.8x

Potential Share Price

NOK 0.34

Ronny Hermansen, CEO



Ronny Hermansen has been at the Company since 2014 and holds an MsBA (Cand. Merc) from Aalborg University, Denmark. He has over 20 years of experience in the international diagnostics industry, including his former role as Group CFO at Axis-Shield plc (LSE), where he was based in London until the company was acquired by Alere Inc. in December 2011. Hermansen has been involved with Genetic Analysis since 2014 and previously held the position of Vice President of Finance in Operations at Nycomed Amersham (later GE Healthcare).

Christina Casén, Senior Vice President Clinical & Medical Affairs



Christina Casén has been in the Company since 2010 and holds a Master of Science degree in Molecular Cell Biology and has over 20 years of experience in the international diagnostics industry, including roles at Abbott Diagnostic Division, Axis-Shield plc, and several biotech startups. Casén possesses extensive expertise in international network development, global project management within clinical research, and the commercialization of products.

Kari Furu, Head of Commercial



Kari Furu graduated from the University of Oslo in 2012 with a PhD in Molecular Biology. Furu has over 10 years of experience in molecular biology research, product development, and in vitro diagnostics, and has previously worked at the Cancer Registry of Norway and the University of Oslo. She has been involved with Genetic Analysis as Chief Technical Officer since 2021.

Lars Tiller, Head of Operations




Lars Tiller has been in the Company since 2022 and has over 15 years of experience in the human in vitro diagnostics industry, having held positions at companies such as Axis-Shield PoC, Alere Technologies, and Nabas. Tiller has extensive experience in production management, with a strong focus on quality and cost efficiency. He also holds an MSc in Biotechnology from the Norwegian University of Life Sciences (NMBU).

Morten Jurs, Chairman of the board



Morten Jurs has experience from several public and private growth companies including leadership roles at SpinChip Diagnostics AS, Pronova BioPharma ASA, and Kitron ASA. He has been involved in guiding companies through major changes and has a strong track record in helping businesses grow and succeed. Morten is currently the CEO of SpinChip Diagnostics, Morten played a key role in the recent acquisition of SpinChip by bioMérieux for NOK 1.6bn, demonstrating his ability to lead complex business transactions.

Camilla Huse Bondesson, Board member



Camilla Huse Bondesson has been a board member since 2020 and holds an Executive MBA from Stockholm University and has over 30 years of international operational and strategic experience from senior positions within the biotechnology sector. Her previous roles include Head of Behring Diagnostica AB, International Product Manager at Biacore, Marketing Director at Amersham Biosciences (now Cytiva), and VP Marketing at Gyros AB. Since 2004, Bondesson has worked as a consultant and partner at Conlega and possesses extensive experience in board work for both listed and unlisted companies.

**Ove Öhman, Board member**


Ove Öhman is a Swedish serial entrepreneur with a proven track record in the life science and diagnostics industries. Over the past two decades, he has founded or co-founded several companies, including Åmic (1998), Ginolis (2008), Fiomi (2011), Vanadis (2014), Astrego (2016), Moleculent (2021), and Readily Diagnostics (2022). He has served as CEO in several of these ventures and currently holds the position of Chairman of the Board at Readily Diagnostics. He is also a board member of Enablers, Moleculent, and Samplefacts.

**Thorvald Steen, Board member**

Thorvald Steen was educated from Royal Norwegian Naval Academy in 1984. He left the Navy in 1990 and was employed by Norsk Hydro, Oil & Gas, which he left in 1999. For 20 years, he held various roles in the financial industry, both as a general manager and as a senior corporate advisor. The past four years Thorvald has been a private investor, board member and adviser, and holds positions as chairman and board member across diverse businesses.



**Rune Sørum, Board member**

Rune Sørum has been a board member since 2010 and holds a degree in Business Administration from Copenhagen Business School. He is currently a partner at Televenture Management and has previously worked with private investments, serving as a senior advisor to European companies operating in both Asia and the Middle East. Sørum has also held several board positions in Norwegian investment firms.



**Richard Kurtz, Board member**

Richard is the Vice President of Corporate Business Development for Bio-Rad Laboratories, a life science research and clinical diagnostics company. In his current role, Richard executes corporate strategies to deliver long-term company growth, focusing on acquisitions, strategic investments and corporate partnerships in both Life Science and Clinical Diagnostics. Richard has over 20 years of industry experience. Previously, Richard was the Marketing Director for the Life Science Gene Expression Division. He has extensive experience in strategic business planning, technology assessment, product development and commercialization. Richard received his Ph.D in Molecular Biology from Northwestern University prior to transitioning into industry.



Base scenario (NOKm)	2023	2024	2025E	2026E	2027E	2028E
Sales revenue	14.1	15.9	17.5	28.9	40.6	52.0
Other income	9.0	4.8	5.1	3.0	3.0	3.0
Total income	23.2	20.7	22.6	31.9	43.6	55.0
COGS	-4.4	-3.1	-5.0	-8.4	-10.9	-13.2
Gross profit	18.7	17.6	17.7	23.4	32.7	41.8
Gross margin (adj.)	69%	80%	72%	71%	73%	75%
Employee benefit expenses	-23.6	-19.3	-14.7	-16.7	-19.4	-23.1
Other expenses	-13.5	-7.5	-6.3	-6.9	-7.9	-8.3
Other gains and losses	0.0	0.3	-0.3	0.0	0.0	0.0
EBITDA	-18.3	-9.0	-3.6	-0.2	5.4	10.4
EBITDA margin (adj.)	-193%	-87%	-50%	-11%	6%	14%
Depreciation and amortization	-5.6	-5.2	-5.4	-5.3	-4.6	-3.7
EBIT	-23.8	-14.2	-9.0	-5.5	0.9	6.7
EBIT margin (adj.)	-232%	-120%	-81%	-29%	-5%	7%
Financial income	0.4	0.4	0.3	0.3	0.3	0.3
Financial expenses	-0.3	-1.0	-0.4	-0.3	-0.3	-0.3
EBT	-23.8	-14.8	-9.1	-5.5	0.9	6.7
Taxes	0.0	0.0	0.0	0.0	0.0	0.0
Net result	-23.8	-14.8	-9.1	-5.5	0.9	6.7
Net margin (adj.)	-232%	-123%	-81%	-30%	-5%	7%
Shares outstanding (millions)	69.1	69.1	69.1	69.1	69.1	69.1
Earnings per share (EPS)	neg.	neg.	neg.	neg.	0.0	0.1



Bull scenario (NOKm)	2023	2024	2025E	2026E	2027E	2028E
Sales revenue	14.1	15.9	19.6	36.3	51.1	68.0
Other income	9.0	4.8	5.0	3.0	3.0	3.0
Total income	23.2	20.7	24.6	39.3	54.1	71.0
COGS	-4.4	-3.1	-5.3	-9.4	-12.9	-16.3
Gross profit	18.7	17.6	19.2	30.0	41.3	54.7
Gross margin (adj.)	69%	80%	73%	74%	75%	76%
Employee benefit expenses	-23.6	-19.3	-15.2	-18.1	-21.0	-24.0
Other expenses	-13.5	-7.5	-6.6	-8.0	-9.2	-10.9
Other gains and losses	0.0	0.3	0.0	0.0	0.0	0.0
EBITDA	-18.3	-9.0	-2.6	3.9	11.1	19.8
EBITDA margin (adj.)	-193%	-87%	-39%	3%	16%	25%
Depreciation and amortization	-5.6	-5.2	-5.4	-5.3	-4.8	-4.3
EBIT	-23.8	-14.2	-8.0	-1.4	6.2	15.5
EBIT margin (adj.)	-232%	-120%	-67%	-12%	6%	18%
Financial income	0.4	0.4	0.3	0.3	0.3	0.3
Financial expenses	-0.3	-1.0	-0.4	-0.3	-0.3	-0.3
EBT	-23.8	-14.8	-8.1	-1.4	6.3	15.6
Taxes	0.0	0.0	0.0	0.0	0.0	0.0
Net result	-23.8	-14.8	-8.1	-1.4	6.3	15.6
Net margin (adj.)	-232%	-123%	-67%	-12%	6%	19%
Shares outstanding (millions)	69.1	69.1	69.1	69.1	69.1	69.1
Earnings per share (EPS)	neg.	neg.	neg.	neg.	0.1	0.2



Bear scenario (NOKm)	2023	2024	2025E	2026E	2027E	2028E
Sales revenue	14.1	15.9	14.8	17.3	19.8	21.6
Other income	9.0	4.8	5.0	3.0	3.0	3.0
Total income	23.2	20.7	19.8	20.3	22.8	24.6
COGS	-4.4	-3.1	-4.2	-5.0	-5.7	-6.2
Gross profit	18.7	17.6	15.6	15.3	17.1	18.4
Gross margin (adj.)	69%	80%	71%	71%	71%	71%
Employee benefit expenses	-23.6	-19.3	-14.6	-15.3	-16.2	-17.1
Other expenses	-13.5	-7.5	-6.4	-6.9	-7.3	-7.8
Other gains and losses	0.0	0.3	0.0	0.0	0.0	0.0
EBITDA	-18.3	-9.0	-5.4	-6.9	-6.4	-6.5
EBITDA margin (adj.)	-193%	-87%	-70%	-58%	-48%	-44%
Depreciation and amortization	-5.6	-5.2	-5.4	-5.3	-4.6	-3.7
EBIT	-23.8	-14.2	-10.8	-12.3	-11.0	-10.2
EBIT margin (adj.)	-232%	-120%	-107%	-88%	-71%	-61%
Financial income	0.4	0.4	0.3	0.3	0.3	0.3
Financial expenses	-0.3	-1.0	-0.4	-0.3	-0.3	-0.3
EBT	-23.8	-14.8	-11.0	-12.3	-11.0	-10.1
Taxes	0.0	0.0	0.0	0.0	0.0	0.0
Net result	-23.8	-14.8	-11.0	-12.3	-11.0	-10.1
Net margin (adj.)	-232%	-123%	-108%	-89%	-71%	-61%
Shares outstanding (millions)	69.1	69.1	69.1	69.1	69.1	69.1
Earnings per share (EPS)	neg.	neg.	neg.	neg.	neg.	neg.



Disclaimer

These analyses, documents and any other information originating from AG Equity Research AB (Henceforth "AG") are created for information purposes only, for general dissipation and are not intended to be advisory. The information in the analysis is based on sources, data and persons which AG believes to be reliable. AG can never guarantee the accuracy of the information. The forward-looking information found in this analysis are based on assumptions about the future, and are therefore uncertain by nature and using information found in the analysis should therefore be done with care. Furthermore, AG can never guarantee that the projections and forward-looking statements will be fulfilled to any extent. This means that any investment decisions based on information from AG, any employee or person related to AG are to be regarded to be made independently by the investor. These analyses, documents and any other information derived from AG is intended to be one of several tools involved in investment decisions regarding all forms of investments regardless of the type of investment involved. Investors are urged to supplement with additional relevant data and information, as well as consulting a financial adviser prior to any investment decision. AG disclaims all liability for any loss or damage of any kind that may be based on the use of analyzes, documents and any other information derived from AG.

Conflicts of Interest and impartiality

To ensure AG's independence, AG has established compliance rules for analysts. In addition, all analysts have signed an agreement in which they are required to report any and all conflicts of interest. These terms have been designed to ensure that *COMMISSION DELEGATED REGULATION (EU) 2016/958 of 9 March 2016, supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council with regard to regulatory technical standards for the technical arrangements for objective presentation of investment recommendations or other information recommending or suggesting an investment strategy and for disclosure of particular interests or indications of conflicts of interest*. Compliance policy: <https://analystgroup.se/interna-regler-ansvarsbegransning/> (Swedish)

Other

This analysis is a task analysis. This means Analyst Group has received payment for doing the analysis. The Principal, **Genetic Analysis AS** (furthermore "the Company") has had no opportunity to influence the parts where Analyst Group has had opinions about the Company's future valuation or anything that could constitute an objective assessment.

The parts that the Company has been able to influence are the parts that are purely factual and objective.

The analyst does not own shares in the Company.

This analysis is copyright protected by law © AG Equity Research AB (2014-2025). Sharing, dissemination or equivalent action to a third party is permitted provided that the analysis is shared unchanged.